期刊
IMMUNOLOGICAL REVIEWS
卷 303, 期 1, 页码 168-186出版社
WILEY
DOI: 10.1111/imr.13011
关键词
antibody-mediated rejection; desensitization; plasma cell; transplantation
类别
资金
- Novartis
- Sanofi
- National Institute of Allergy and Infectious Diseases [R21AI142264, RO1AI154932]
Solid organ transplantation is a life-saving procedure that has made significant progress in the past 70 years, particularly in T-cell-targeted immunosuppression and organ allocation systems. However, humoral alloimmune responses remain a major challenge, especially for patients with preexisting anti-HLA antibodies. Therapies to target plasma cells, the source of antibody production, have had limited effectiveness in reducing antibody levels.
Solid organ transplantation is a life-saving procedure for patients with end-stage organ disease. Over the past 70 years, tremendous progress has been made in solid organ transplantation, particularly in T-cell-targeted immunosuppression and organ allocation systems. However, humoral alloimmune responses remain a major challenge to progress. Patients with preexisting antibodies to human leukocyte antigen (HLA) are at significant disadvantages in regard to receiving a well-matched organ, moreover, those who develop anti-HLA antibodies after transplantation face a significant foreshortening of renal allograft survival. Historical therapies to desensitize patients prior to transplantation or to treat posttransplant AMR have had limited effectiveness, likely because they do not significantly reduce antibody levels, as plasma cells, the source of antibody production, remain largely unaffected. Herein, we will discuss the significance of plasma cells in transplantation, aspects of their biology as potential therapeutic targets, clinical challenges in developing strategies to target plasma cells in transplantation, and lastly, novel approaches that have potential to advance the field.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据